---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-005528"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2022-04-08T23:59:59+00:00"
generated_at: "2026-06-26T08:30:35.122623+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences amends CEO Szwarcberg's equity vesting acceleration terms

## Summary
- Amendment to CEO Javier Szwarcberg's offer letter dated April 6, 2022.
- Vesting acceleration under Severance Plan for Second Stock Option now only applies to Change in Control with effective date on or after January 3, 2023.
- All other terms and conditions of the offer letter remain unchanged.

## SEC filing metadata
- accession: 0000950170-22-005528
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2022-04-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017022005528/0000950170-22-005528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017022005528/sprb-20220406.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-005528
- JSON: https://secwatch.observer/filing/0000950170-22-005528.json
- Plain text: https://secwatch.observer/filing/0000950170-22-005528.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.